Derma Sciences Inc. (NASDAQ:DSCI) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “

Separately, TheStreet raised Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.35.

Derma Sciences (NASDAQ:DSCI) traded down 0.43% on Tuesday, reaching $4.58. 10,051 shares of the company’s stock were exchanged. The company’s market capitalization is $129.64 million. The company has a 50 day moving average price of $4.71 and a 200-day moving average price of $4.19. Derma Sciences has a 1-year low of $2.85 and a 1-year high of $5.99.

Derma Sciences (NASDAQ:DSCI) last released its earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.16. Derma Sciences had a negative return on equity of 11.74% and a negative net margin of 21.19%. The company earned $22.20 million during the quarter, compared to the consensus estimate of $22.40 million. On average, equities research analysts anticipate that Derma Sciences will post ($0.04) earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in shares of Derma Sciences by 23.3% in the first quarter. Renaissance Technologies LLC now owns 541,800 shares of the company’s stock worth $1,680,000 after buying an additional 102,500 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock worth $364,000 after buying an additional 73,911 shares in the last quarter. Franklin Resources Inc. boosted its stake in Derma Sciences by 2.5% in the first quarter. Franklin Resources Inc. now owns 2,684,500 shares of the company’s stock worth $8,322,000 after buying an additional 65,192 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in Derma Sciences during the second quarter worth approximately $202,000. Finally, Granahan Investment Management Inc. MA boosted its stake in Derma Sciences by 5.1% in the first quarter. Granahan Investment Management Inc. MA now owns 1,028,460 shares of the company’s stock worth $3,188,000 after buying an additional 50,142 shares in the last quarter. Institutional investors and hedge funds own 62.44% of the company’s stock.

About Derma Sciences

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

5 Day Chart for NASDAQ:DSCI

Receive News & Stock Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related stocks with our FREE daily email newsletter.